Retinal Vein OcclusionNCT07106268
Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
An observational study of Retinal Vein Occlusion, run by Tianjin Medical University Eye Hospital at 1 site in China.
Trial summary
the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is: What are the changes in protein in the aqueous humor during treatment in patients who are sensitive… Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Retinal Vein Occlusion
- Type of treatment
- Injection or infusion
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 Mar 2023to 30 Sep 2025
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients diagnosed with retinal vein occlusion with macular edema
Who may be able to join
- Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
- Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
- Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
- Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
- The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram
Who cannot join
- Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
- Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
- Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Aqueous Humor Proteome Analysis in Conbercept-treated Retinal Vein Occlusion With Macular Edema
the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:
What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?
- Conditions
- Retinal Vein Occlusion
- Medical subject headings
- Retinal Vein Occlusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with central retinal vein occlusion | Received three injections of the anti-VEGF drug Conbercept | |
| Patients with branch retinal vein occlusion | Received three injections of the anti-VEGF drug Conbercept | |
| Cataract patients without other eye diseases and other chronic diseases | Undergo cataract surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Central retinal thickness
The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients
Measured: March 2023 - June 2024
Secondary outcomes (1)
Best corrected visual acuity
BCVA was measured using logarithm of the minimum angle of resolution (LogMAR) chart
Measured: March 2023 - June 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2025
- Study start1 Mar 2023
- Primary completion30 Sep 2025 (estimated)
- Study completion30 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinal Vein OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Tianjin Medical University Eye Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chuanzhen Zheng, Tianjin Medical University Eye Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07106268
- Sponsor's protocol ID
- MR-12-24-035937
- Status last verified
- Aug 2025
- First submitted
- 30 Jul 2025
- Last updated
- 7 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aqueous Humor Proteome Analysis in Conbercept-treated Retinal Vein Occlusion With Macular Edema
- ClinicalTrials.gov ID
- NCT07106268
- Acronym / sponsor ID
- MR-12-24-035937
- Conditions
- Retinal Vein Occlusion
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Tianjin Medical University Eye HospitalUniversity, hospital or other
- Study start
- 1 Mar 2023 (actual)
- Primary completion
- 30 Sep 2025 (estimated)
- Study completion
- 30 Sep 2025 (estimated)
- First posted
- 6 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:
What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with central retinal vein occlusion | – | –Received three injections of the anti-VEGF drug Conbercept |
| Patients with branch retinal vein occlusion | – | –Received three injections of the anti-VEGF drug Conbercept |
| Cataract patients without other eye diseases and other chronic diseases | – | –Undergo cataract surgery |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with retinal vein occlusion with macular edema
Key inclusion criteria (5 listed)
- Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
- Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
- Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
- Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
- The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram
Key exclusion criteria (3 listed)
- Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
- Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
- Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Central retinal thickness
Time frame: March 2023 - June 2024
The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients
1 secondary outcome
Best corrected visual acuity
Time frame: March 2023 - June 2024
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Retinal Vein Occlusion
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
Not yet recruitingPhase 4
Iopidine to Decrease Intraocular Pressure Rise After Injections
Macular Degeneration, Diabetic Retinopathy
Recruiting
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal Vein Occlusion (RVO)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinal Vein Occlusion, run by Tianjin Medical University Eye Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Central retinal thickness (time frame: March 2023 - June 2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2025.